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Abstract
Background: Postoperative nausea and vomiting (PONV) is one of the most common adverse outcomes after
strabismus surgery. The primary outcome of this prospective, randomized, double-blind study was to compare the
incidences of nausea or vomiting, and patient satisfaction of ondansetron and ramosetron after strabismus surgery
under general anesthesia. The secondary outcome was to investigate whether the number of involved extraocular
muscles (EOMs) in strabismus surgery was related to PONV.
Methods: One hundred and five patients (aged 18–60 years) undergoing strabismus surgery were allocated randomly
to one of the three groups: placebo, ondansetron, or ramosetron. Patients received 2 ml placebo, 4 mg ondansetron, or
0.3 mg ramosetron at the end of surgery. Each of the three groups was subdivided into two subgroups according to the
number of EOMs involved in the surgery: subgroup S, single-muscle correction; subgroup M, multiple-muscle correction.
The incidences of nausea or vomiting, and patient satisfaction at 2, 24 and 48 h after surgery were analyzed as primary
outcome. With regard to subgroups S and M in the placebo, ondansetron and ramosetron groups, incidences of nausea
or vomiting, and patient satisfaction at 2, 24 and 48 h after surgery were analyzed as seconadary outcome.
Results: The incidence of nausea was significantly lower in the ramosetron group at 2 h (9.4 %) than in the placebo (45.
2 %) and ondansetron (34.7 %) groups (P < 0.05). The incidence of nausea was also significantly lower in the ramosetron
group at 24 h than in the other groups (P < 0.05). Patients in the ramosetron group were more satisfied at 2 h (8.11 ± 0.
98) and 24 h (8.50 ± 0.67) after surgery than those in the other groups (P < 0.05). With regard to subgroups S and M in
the placebo, ondansetron and ramosetron groups, there were no significant differences in either the incidence of
nausea or patient satisfaction.
Conclusion: Ramosetron has superior antiemetic activity to ondansetron in adult strabismus surgery patients.
The number of EOMs involved in strabismus surgery was not related to the incidence of PONV.
Trial registration: Clinical Research Information Service (CRiS) Identifier: KCT0000688. Date of registration:
27 February 2013.
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Background
Postoperative nausea and vomiting (PONV) is one of the
most common adverse outcomes after strabismus surgery
under general anesthesia, with an incidence of 37–80 %
[1–4]. PONV may delay discharge from hospital or cause
unexpected hospitalization in severe cases not only that it
lowers patient’s satisfaction after surgery.
There are several known methods for PONV prophy-
laxis. Serotonin (5-HT3) receptor antagonists are recom-
mended as the first-line regimen for PONV prophylaxis
[5]. Ondansetron, the first 5-HT3 receptor antagonist used
clinically for the prevention and management of PONV,
acts less selectively on the 5-HT3 receptor than other
5-HT3 antagonists. Systemic review has revealed that
the prophylactic effect of ondansetron on nausea is ques-
tionable although it has fine prophylactic effect on vomit-
ing [6, 7]. Ramosetron, a newer 5-HT3 antagonist, has
higher affinity to the 5-HT3 receptor and longer duration
of action, and has a similar or greater prophylactic effect
on PONV compared with older 5-HT3–receptor antago-
nists such as granisetron and ondansetron [8–10].
Traction of extraocular muscles (EOMs) is one of the
factors that trigger PONV after strabismus surgery,
which induces the oculoemetic reflex [11]. We hypoth-
esized that more PONV would occur as the number of
EOMs involved in strabismus surgery increases, causing
more muscle traction. To our knowledge, no previous
reports of the relationship between the numbers of in-
volved EOMs and PONV have been published.
Thus, we primarily designed this prospective, random-
ized, double-blind study to compare the incidences of
nausea or vomiting, and patient satisfaction of ondanse-
tron and ramosetron after strabismus surgery under gen-
eral anesthesia in patients aged > 18 years. The secondary
outcome was to investigate whether the number of in-
volved extraocular muscles (EOMs) in strabismus surgery
was related to PONV.
Methods
Study population
One hundred twenty patients aged between 18 and
60 years, ASA physical status I and II, and scheduled for
strabismus surgery under general anesthesia were enrolled
from April 2011 to April 2012 in this prospective, ran-
domized, double-blind clinical study. Patients who took
any analgesics, steroids or antiemetics 24 h before surgery,
or who had gastrointestinal diseases were excluded.
Recruited patients were allocated randomly to receive
one of the following three drugs at the end of surgery:
intravenous (IV) placebo (normal saline), ondansetron
(4 mg), or ramosetron (0.3 mg) [12, 13]. A computer-
ized randomization list was generated, and identical sy-
ringes (2 ml total) containing each drug were prepared
by personnel not involved in the study, according to
the list.
Study protocol
All patients were allowed to take solid food up to 8 h before
surgery and water up to 2 h before surgery. No premedica-
tion was administered to the patients. Electrocardiogram,
non-invasive blood pressure, heart rate, and pulse oximetry
were measured continuously at 5-min intervals, starting
from the time of arrival in the operating room. General
anesthesia was induced with 2 mg/kg propofol and 0.6 mg/
kg rocuronium. After tracheal intubation, anesthesia was
maintained with 1.5–2 vol.% sevoflurane, medical air in
oxygen [fraction of inspired O2 (FiO2) = 0.5], and continu-
ously infused IV remifentanil 0.05–0.1 μg/kg/min, keeping
end-tidal CO2 between 35 and 40 mmHg throughout the
surgery. Ringer’s lactate solution was administered at 6–
8 ml/kg/h during surgery. The nasopharyngeal temperature
was monitored and maintained at 36 ± 1 °C throughout
surgery using a warming pad. The types of strabismus
surgery included were unilateral rectus muscle recession,
unilateral rectus muscle resection, bilateral rectus muscle
recession, and bilateral rectus muscle resection. At the end
of the surgical procedure, sevoflurane and remifentanil
administration were discontinued. IV 0.2 mg/kg pyridostig-
mine and 0.008 mg/kg glycopyrrolate were administered
for reversal of muscle relaxation, along with the assigned
study drug. The trachea was extubated when spontaneous
respiration of the patient was adequate.
After the operation, the patients were transferred to
the postanesthesia care unit. Every episode of nausea or
vomiting was recorded during the first 2 h after surgery,
and the presence of nausea at 2 h after surgery was
asked by a member of the nursing staff who was blinded
to the study drug used. She also filled out the data table
including the followings: presence of nausea and vomit-
ing, use of rescue antiemetics, patient’s satisfaction, de-
gree of pain, use of rescue analgesics, and presence of
adverse effects of the study drugs, such as headache, diz-
ziness, or drowsiness. The patients were asked to grade
their satisfaction from 0 to 10 (VRS, verbal rating scale),
where 0 represents total dissatisfaction and 10 repre-
sents the most satisfactory subjective answer. The degree
of pain was recorded using a visual rating scale (VRS)
with options from 0 (not painful at all) to 10 (extremely
painful).
If VRS score was > 3 for > 5 min, 30 mg IV ketorolac
was administered for rescue analgesia. If patients com-
plained of severe pain (VRS > 7), 1 μg/kg fentanyl was
administered. When patients complained of nausea or
vomitted, 10-mg IV metoclopramide was administered
as a rescue antiemetic.
Patients were discharged from the hospital unless they
showed severe complications of anesthesia, such as fever
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or desaturation due to laryngospasm or atelectasis. At
24 and 48 h after surgery, a resident of the Department
of Ophthalmology who was also blinded to the study
drug used completed the data table via telephone call.
After completion of data collection, patients were subdi-
vided into two groups according to the number of EOMs
involved in the surgery: subgroup S, single-muscle correc-
tion; and subgroup M, multiple-muscle correction.
Statistical analyses
To estimate the required sample size, a power analysis
was used. We aimed for an 80 % probability (β = 0.2) of
detecting a 50 % difference with a significance level (α)
of 0.05, based on the incidence of PONV being 50 % in
the placebo group and 20 % in the ramosetron group from
our pilot study; thus 25 patients per group were required.
To account for exclusion of some patients, we enrolled 35
patients in each group. Statistical analysis was performed
using the SPSS, version 18.0 (SPSS, Chicago, IL, USA).
Demographic data were analyzed by Student’s t-test. Dif-
ferences in the incidence of nausea and vomiting, and
use of rescue antiemetics were analyzed by χ2 test. Pa-
tient’s satisfaction and pain were compared using one-
way ANOVA with post hoc Bonferroni correction for
multiple comparisons; data are presented as mean ± SD.
Intention-to-treat (ITT) analysis was conducted using
last-observation-carried-forward (LOCF) imputation for
missing values. A value of P < 0.05 was considered to
indicate statistical significance.
Results
Among 120 patients recruited, 12 patients were excluded
because they did not meet inclusion criteria; they
showed ASA physical status >2. Another three patients
were excluded because they did not agree to participate.
Hence, 105 were randomly allocated to three groups.
Among 16 follow-up loss patients, three patients and 13
patients did not respond to 24 h and 48 h telephone call,
respectively (Fig. 1). Since persistent prophylactic effect
on PONV was in concern, all the follow-up loss patients
were excluded. There were no significant differences in
patients’ characteristics, Apfel’s four risk factors for
PONV (female gender, nonsmoking, prior history of mo-
tion sickness or PONV, and the use of intraoperative
opioids) [14], and the duration of surgery and anesthesia
among the groups (Table 1).
Assessed for eligibility (n = 120)
Excluded  (n = 15)
♦ Not meeting inclusion criteria (n = 12)
♦ Declined to participate (n = 3)
♦ Other reasons (n = 0 )
Analysed  (n = 31)
♦ Excluded from analysis (n = 0)
Lost to follow-up (n = 4)
Discontinued intervention (n = 0)
Allocated to intervention (n = 35)
♦ Received allocated intervention (n = 35 )
♦ Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 9)
Discontinued intervention (n = 0)
Allocated to intervention (n = 35)
♦ Received allocated intervention (n = 35)
♦ Did not receive allocated intervention (n = 0)
Analysed  (n = 26)




Randomized (n = 105)
Enrollment
Allocated to intervention (n = 35)
♦ Received allocated intervention (n = 35)
♦ Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 3)
Discontinued intervention (n = 0)
Analysed (n = 32)
♦ Excluded from analysis (n = 0)
Fig. 1 Flow diagram of the study
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Fig. 2 Incidence of nausea. Per- protocol analysis (a) and intention-to-treat analysis (b). *P < 0.05 versus placebo group, †P < 0.05 versus
ondansetron group
Table 1 Patients’ characteristics and clinical data
Placebo Ondansetron Ramosetron
(n = 31) (n = 26) (n = 32)
Age, years 34.10 ± 15.14 35.69 ± 17.13 34.13 ± 13.66
Weight, kg 61.38 ± 9.50 65.32 ± 10.63 59.64 ± 10.39
Height, cm 163.82 ± 10.79 167.70 ± 9.63 165.49 ± 10.33
Sex, M/F 14/17 14/12 13/19
PONV Hx., n (%) 2 (6.45) 2 (7.69) 2 (6.25)
Motion sickness, n (%) 12 (38.71) 10 (38.46) 13 (40.63)
Non-smoker, n (%) 20 (64.52) 17 (65.38) 21 (65.63)
Duration of surgery, min 23.90 ± 3.82 24.32 ± 3.72 24.05 ± 2.36
Duration of anesthesia, min 35.24 ± 7.92 35.95 ± 4.26 36.64 ± 4.97
Data are means ± SD or numbers. F female, M male
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The total incidences of nausea were 29.2 % (26/89) at
2 h, 14.6 % (13/89) at 24 h, and 1.1 % (1/89) at 48 h after
surgery. The incidence of nausea was significantly
lower in the ramosetron group at 2 h (9.4 %) than in
the placebo (45.2 %) and ondansetron (34.6 %) groups
(P < 0.05). The incidence of nausea was also signifi-
cantly lower in the ramosetron group at 24 h (3.1 %) than
in the placebo (22.6 %) and ondansetron (19.2 %) groups
(P < 0.05). There was no significant difference in the inci-
dence of nausea at 48 h after surgery. The ondansetron
group, comparing with the placebo group, showed signifi-
cantly lower incidence of nausea only at 2 h after surgery
(Fig. 2a). The ITT analysis using LOCF imputation for
missing values revealed similar results (Fig. 2b). No patient
showed vomiting after surgery. The incidence of rescue
antiemetic use was identical significantly lower in the
ramosetron group than in the other groups. No patients
required fentanyl as rescue analgesics (Table 2).
Patients in the ramosetron group were more satisfied
at 2 h (8.11 ± 0.98) and 24 h (8.50 ± 0.67) after surgery
than those in the placebo (6.84 ± 1.34, 7.25 ± 1.29, re-
spectively at 2 h and 24 h) and those in the ondansetron
(7.28 ± 1.83, 7.27 ± 1.59, respectively at 2 h and 24 h)
groups (P < 0.05). There was no significant difference in
satisfaction in the patients at 48 h after surgery among
any of the groups. The placebo and ondansetron groups
showed no significant difference in patient satisfaction at
all times after surgery (Fig. 3). There were no significant
differences in the degree of pain and incidence of adverse
effects of antiemetics among the groups (Tables 3 and 4).
With regard to subgroups S and M in the placebo,
ondansetron and ramosetron groups, there were no sig-
nificant differences in either the incidence of nausea or
patient satisfaction (Figs. 4 and 5). The ITT analysis also
showed similar results.
Discussion
PONV is one of the most common causes of unexpected
hospitalization in ambulatory strabismus surgery [15].
Although the mechanism of PONV after strabismus
surgery are not still clearly identified, traction of EOMs,
besides from agents used for general anesthesia, is a
well-known risk factor for PONV [11, 16, 17].
In the present study, the incidence of postoperative nau-
sea without prophylaxis was 45.2 % at 2 h and 22.6 % at
24 h after strabismus surgery. This is slightly higher than
the previously reported incidence of PONV after strabis-
mus surgery [18–20]. Meanwhile, the incidence of postop-
erative vomiting without prophylaxis was 0 % in this study
unlike those previous studies. However, analysis in these
Table 2 Use of rescue analgesics and antiemetics in
postanestheia unit
Placebo Ondansetron Ramosetron
(n = 31) (n = 26) (n = 32)
Use of rescue analgesics, n (%) 17 (54.84) 14 (53.85) 18 (56.25)
Use of rescue antiemetics, n (%) 14 (45.2) 9 (34.6)* 3 (9.4)*†
*P < 0.05 versus placebo group, †P < 0.05 versus ondansetron group
Fig. 3 Patient satisfaction. VRS, verbal rating scale. *P < 0.05 versus placebo group, †P < 0.05 versus ondansetron group
Table 3 Degree of pain
Placebo Ondansetron Ramosetron P
value(n = 31) (n = 26) (n = 32)
VAS
2 h 3.81 ± 1.87 3.35 ± 1.52 3.43 ± 1.74 ns
24 h 2.58 ± 1.52 2.08 ± 1.41 2.19 ± 1.31 ns
48 h 1.32 ± 1.40 1.58 ± 2.02 1.44 ± 1.19 ns
Data are means ± SD. VAS visual analogue scale
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differences is complicated because of differences in study
population and anesthetic techniques.
Drugs used to alleviate PONV act on serotonergic,
dopaminergic, histaminergic, or cholinergic receptors in
the chemoreceptor trigger zone [4, 21, 22]. Among these,
the 5-HT3 receptor antagonists prevents the emetogenic
signal from tranmission to the nucleus tractus solitarii,
where most vagal afferents terminate, by regulating sero-
tonin release. 5-HT3 receptor antagonists exert their effect
by inhibiting the binding of serotonin to the 5-HT3 recep-
tors; they are copious in nucleus tractus solitarii and the
chemoreceptor trigger zone which, in turn, project signals
to the emetic center located in the brainstem [23, 24].
Among 5-HT3 receptor antagonists, ondansetron was
the first agent used clinically for PONV. A dose of 4 mg
IV at the end of surgery has been reported to be effective
for PONV prophylaxis, with a relatively short plasma half-
life (3.5–4.7 h) and duration of action (~12 h) [13]. Tramer
et al. [7] reported less pronounced antiemetic effect of
ondansetron comparing to its anti-vomiting effect. Ondan-
setron, comparing with placebo, did not improve the pa-
tient’s satisfaction at any time point although it reduced
the incidence of nausea only at 2 h after in our study.
Meanwhile, ramosetron, a newer 5-HT3 receptor an-
tagonist, has greater affinity for 5-HT3 receptors and
greater potency in consequence, and a longer plasma
half life (5.8 ± 1.2 h) and duration of action than other 5-
HT3 receptor antagonists [6, 8, 9]. Whether ramosetron
has a greater antiemetic effect than other 5-HT3 recep-
tor antagonists is controversial [25–30]. Our data sug-
gest that ramosetron has a greater antiemetic effect than
ondansetron within 24 h after strabismus surgery. Stra-
bismus surgery is known to be a particularly emetogenic
surgical procedure [1, 3, 31]. Improving patients’ satis-
faction and stronger anti-emetic effect within 24 h after
surgery comparing to ondansetron suggest that ramose-
tron should be administered after strabismus surgery to
prevent nausea, because most postoperative nausea oc-
curred within 24 h after surgery in our study population.
Meanwhile, the antiemetic effect of ramosetron at 48 h
after surgery was similar to that of ondansetron, which
corresponds to the report of Halm et al. [10].
Among various ocular surgeries under general anesthesia,
the strabismus surgery is one of the most common surger-
ies that would result in PONV. Traction of EOMs induces
the ocluoemetic reflex and oculocardiac relex, causing
Table 4 Adverse effects of antiemetics
Placebo Ondansetron Ramosetron P value
(n = 31) (n = 26) (n = 32)
Headache
2 h 7 (22.6) 3 (11.5) 9 (28.1) ns
24 h 7 (22.6) 2 (7.7) 3 (9.4) ns
48 h 1 (3.2) 0 (0) 0 (0) ns
Dizziness
2 h 7 (22.6) 4 (15.4) 4 (12.5) ns
24 h 1 (3.2) 2 (7.7) 2 (6.3) ns
48 h 0 (0) 0 (0) 0 (0) ns
Drowsiness
2 h 3 (9.7) 4 (15.4) 2 (6.3) ns
24 h 0 (0) 0 (0) 1 (3.1) ns
48 h 0 (0) 0 (0) 0 (0) ns
Data are numbers (percentages)
Fig. 4 Incidence of nausea regarding the number of extraocular muscles involved Subgroup S, single-muscle correction; subgroup M, multiple-muscle
correction. Placebo subgroup S (n = 16), subgroup M (n = 15); Ondansetron subgroup S (n = 12), subgroup M (n = 14); Ramoseron subgroup S (n = 17),
subgroup M (n = 15)
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bradycardia and hypotension, which are risk factors
for PONV [11]. Therefore, we hypothesized that more
PONV would occur as the number of EOMs involved
in strabismus surgery increases, causing more muscle
traction. However, this was not supported by our data.
The effect of traction of EOMs on PONV after strabis-
mus surgery still remains obscure. Further study is
needed to reveal the mechanism of PONV after stra-
bismus surgery.
Pain is a well-known risk factor for PONV, and nausea
but not vomiting is the predominant symptom [11, 16].
As in the present study, several others have reported
that adult patients complain of minimal pain after stra-
bismus surgery with a VAS score < 3 [32, 33]. Moreover,
the degree of pain did not differ among any of our
groups. Therefore, we suggest that pain has less of an
effect on PONV after strabismus surgery.
There are several limitations in our study. First, rela-
tively small number of study population was included.
Second, we did not discriminate the patients who had
strabismus surgery in both eyes from those who had sur-
gery in only one eye. Although we failed to demonstrate
an association between the number of EOMs involved in
strabismus surgery and PONV, the binocularity might
have been related to PONV. Third, the equivalent doses
of ramosetron and ondansetron has not been clearly
identified. Various studies have compared the efficacy
of 0.3 mg of ramosetron with 4–16 mg of ondansetron
[9, 10, 24, 27, 34, 35]. In a previous animal study,
ondansetron did not show a linear dose response curve
[36], which indicates that it is quite complicated to
decide the equivalent doses of ramosetron and ondan-
seston. Further investigation to verify the equivalent
doses of ramosetron and ondansetron is in
contemplation.
Conclusions
In conclusion, the incidence of postoperative nausea
was high until 24 h after strabismus surgery. Therefore,
prevention of postoperative nausea during the 24 h
after strabismus surgery is crucial. Ramosetron had an
antiemetic efficacy greater than that of ondansetron or
placebo during the first 24 h after strabismus surgery in
adult patients. The number of EOMs involved in stra-
bismus surgery was not associated with the incidence
of PONV.
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